Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | LOX | P28300 | 2/20 | 0.38 |
| ▸ | PLK1 | P53350 | 6/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4488736 | 0.98 | L3MBTL1 (0.44) | L3MBTL1LOXPLK1HDAC8HDAC6 | |
| SCHEMBL13368525 | 0.82 | PLK1 (0.47) | L3MBTL1PLK1HDAC8HDAC6HDAC2 | |
| SCHEMBL12094436 | 0.76 | L3MBTL1 (0.49) | L3MBTL1PLAUCA2TDP1HPGD | |
| SCHEMBL26066688 | 0.76 | HTR1A (0.39) | L3MBTL1PLAUTDP1TSHRSMN1; SMN2 | |
| SCHEMBL28150896 | 0.76 | IDH1 (0.53) | L3MBTL1PLK1LMNASLC7A5 | |
| SCHEMBL4476398 | 0.72 | L3MBTL1 (0.50) | L3MBTL1PLK1HDAC6MTNR1AHTT | |
| SCHEMBL13631428 | 0.72 | NPC1 (0.53) | L3MBTL1PLK1HDAC8HDAC6HDAC2 | |
| SCHEMBL27960131 | 0.71 | HDAC8 (0.41) | L3MBTL1PLK1HDAC8HDAC6HDAC2 | |
| SCHEMBL12794022 | 0.69 | HTT (0.40) | PLK1HDAC8HDAC6HDAC2PLAU | |
| SCHEMBL12376574 | 0.68 | RAF1 (0.39) | PLK1HDAC8HDAC6HDAC2PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622464-B2 | Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2009-11-24 | — | — | US | disclosed |
| EP-1487828-B1 | MORPHOLINYL-UREA DERIVATIVES FOR USE OF THE TREATMENT OF INFLAMATORY DISEASES | GLAXO GROUP LTD (GB) | 2008-11-05 | — | — | EP | disclosed |
| US-20060063765-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2006-03-23 | — | — | US | disclosed |
| EP-1487828-A2 | MORPHOLINYL-UREA DERIVATIVES FOR USE OF THE TREATMENT OF INFLAMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003082861-A2 | MORPHOLINYL-UREA DERIVATIVES FOR USE OF THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063765-A1 | Novel compounds | CCR3, NSUN3, CCR1 | L3MBTL1 385/4885LOX 4859/4885PLK1 2923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.